Valuation MyMD Pharmaceuticals, Inc. Boerse Muenchen
Stocks
DQS0
US62856X2018
Blockchain & Cryptocurrency
|
Real-time
Boerse Muenchen
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
+2,616.54% | +1,482.57% |
| 09-30 | Q/C Technologies, Inc. and Sandia National Laboratories Announce Research Collaboration | CI |
| 09-14 | Q/C Technologies, Inc. Appoints Yossef Ehrlichman as Chief Technology Officer | CI |
Company Valuation: MyMD Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 228.1 | 45.39 | 13.17 | 3.168 | 16.63 |
| Change | - | -80.11% | -70.99% | -75.94% | 424.75% |
| Enterprise Value (EV) 1 | 216.7 | 40.69 | 8.293 | -5.339 | 0.8189 |
| Change | - | -81.22% | -79.62% | -164.38% | 115.34% |
| P/E | -7.1x | -2.94x | -1.46x | -0.1x | -0.46x |
| PBR | 9.71x | 3.12x | 1.28x | 0.4x | 1.42x |
| PEG | -0x | 0.1x | 0x | -0x | 0x |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -7.69x | - | - | - | - |
| EV / EBIT | -7.69x | -2.66x | -0.51x | 0.62x | -0.09x |
| EV / FCF | -50.6x | -6.17x | -1.57x | 2.66x | -0.12x |
| FCF Yield | -1.98% | -16.2% | -63.5% | 37.5% | -838% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -2,561 | -1,174 | -533 | -1,115 | -8.662 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | - | - | - | - |
| EBITDA 1 | -28.18 | - | - | - | - |
| EBIT 1 | -28.2 | -15.28 | -16.36 | -8.66 | -9.583 |
| Net income 1 | -29.89 | -15.2 | -4 | -23.36 | -11.63 |
| Net Debt 1 | -11.41 | -4.694 | -4.874 | -8.508 | -15.81 |
| Reference price 2 | 18,180.0182 | 3,450.0034 | 776.1008 | 115.0000 | 3.9900 |
| Nbr of stocks (in thousands) | 12.5 | 13.2 | 17 | 27.6 | 4,167 |
| Announcement Date | 3/31/22 | 3/31/23 | 4/1/24 | 4/11/25 | 4/15/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -64.39x | 8.53x | 39.77x | -.--% | 49.18B | |
| -21.27x | 13.9x | 20.77x | -.--% | 16.11B | |
| -1.21x | - | - | - | 15.94B | |
| -16.16x | 48.54x | -49.78x | - | 10.61B | |
| -7.43x | 11.68x | -32.58x | -.--% | 7.56B | |
| -4.66x | 43.58x | 202.71x | - | 7.38B | |
| -27.4x | 18.04x | 43.63x | - | 7.1B | |
| -12.06x | 47.62x | -334.8x | -.--% | 6.57B | |
| -8.77x | - | - | -.--% | 5.29B | |
| Average | -18.15x | 27.41x | -15.75x | 0% | 13.97B | |
| Weighted average by Cap. | -32.69x | 19.23x | 10.75x | 0% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- QCLS Stock
- DQS0 Stock
- Valuation MyMD Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
